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Introduction
Prions (PrPSc) are infectious proteins that cause transmissible 
spongiform encephalopathies (TSEs).1 They have the capac-
ity to convert a normal cellular protein (PrPC) into a prion and 
thereby propagate an infection. PrPSc and PrPC possess identical 
covalent structures.2 In addition, there are strains of PrPSc that 
have distinct phenotypes and physicochemical properties and yet 
possess identical covalent structures.3 The experimentally deter-
mined structural difference between the two isoforms is entirely 
conformational.1,4
In a protein, the chemical environment of an amino acid is 
dependent upon the conformation of that protein. This means 
that the same amino acid can react differently with the same 
chemical reagent, depending upon the conformation of that pro-
tein.5,6 This phenomenon has been referred to as epitope protec-
tion.7 Some antibodies selectively bind to one PrP isoform but 
not the other even though both isoforms possess identical cova-
lent structures.3,8 This may result from the epitope being exposed 
in one conformation but not in the other. Alternately, since 
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antibodies are large, the steric bulk of the antibody may prevent 
the antibody from binding to an exposed epitope on a PrP iso-
form in its native state. Thus the binding of an antibody may be 
dependent upon the native state conformation of the isoform as 
well as the surface availability of the epitope.
The structures of PrPC and PrPSc have been successfully chem-
ically modified using activated esters (N-hydroxysuccinimide 
esters (NHS)). These activated NHS ester reagents react primar-
ily with the N-terminus of a protein, ε-amino group of lysine 
and hydroxyl groups of tyrosine, serine and threonine.9,10 NHS 
ester based cross-linking reagents have been used to determine 
distance constraints in hamster PrPSc and to map an anti-bovine 
PrP epitope.11,12 NHS esters have been used to attach nanopar-
ticles to human recombinant PrP.13
These efforts indicate that there are a number of amino acids 
on the surface of PrP that will react with a small molecule NHS 
ester. If the reagent reacts with an antibody-recognized surface 
epitope, then it will be covalently modified. If the epitope is not 
on the surface, then it will not be covalently modified, i.e., the 
epitope will remain unchanged. In principle, western blotting © 2012 Landes Bioscience.
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with the primary amines accounts for 12 of the observed modifi-
cations. The few fragments suitable for mass spectrometric analy-
sis revealed the location of three more modifications of tyrosine 
and serine residues (PKP GGW NTG GSR, PKP GGW NTG 
GSR, YPG QGS PGG NR). The remaining five other covalent 
modifications remain unclear. This analysis also revealed that 
identifying a particular covalent modification is difficult to do 
by mass spectrometry even when the protein (rSHaPrP) possesses 
only a single post-translational modification (disulfide bond), let 
alone molecules as complex as PrPC and PrPSc.
The alternate approach of using antibodies with characterized 
epitopes to identify the modified amino acids was tested using 
western blot analysis. Uninfected and infected hamster (263K) 
and mouse (Me7) detergent-solubilized brain extracts were pre-
pared and reacted with tMAB-NHS and Ac-NHS. The resulting 
reaction mixtures were analyzed by western blot. Each western 
blot was probed with one of seven antibodies. Four of these 
antibodies (3F4, AH6, 6D11 and GE8) recognized an epitope 
that was chemically modified by the tMAB-NHS and Ac-NHS 
reagents (Figs. 4A–C and 5A–C). The epitope recognized by the 
other three antibodies (MAB5424, AG4 and 7D9) was not chem-
ically modified by either reagent (Figs. 4D and E and 5D–F). 
The antibodies GE8, 6D11, AG4, 7D9 and MAB5424 were used 
to probe samples containing both hamster and mouse PrP. The 
antibodies 3F4 and AH6 were used to probe only hamster PrP 
or mouse PrP, respectively. In order to minimize secondary anti-
body artifacts, three goat-anti-mouse IgG secondary antibodies 
(Fc-specific, Fab-specific and H + L) were used to probe the same 
blot. It was determined that the Fc-specific secondary antibody 
had no observable secondary antibody artifacts (data not shown).
These results indicate that antibodies can be used to detect 
modified amino acids. The reaction mixtures of uninfected and 
infected (263K) detergent-solubilized extracts of hamster brain 
homogenates (HBH) were analyzed by western blot and probed 
with the antibodies 3F4, GE8 and 6D11 (Fig. 4A–C). In all cases 
the epitopes recognized by these antibodies are completely cova-
lently modified by tMAB-NHS and Ac-NHS reagents when they 
are reacted with the uninfected HBH, but only partially modi-
fied when reacted with the 263K-infected HBH (Fig. 4A–C). It 
is also clear this result is not an artifact of the chemical reaction 
with PrP (Fig. 4D and E). If this were the case, then the west-
ern blots probed with antibodies that are not modified by the 
reagents (MAB5424, AG4 and 7D9) would show substantial dif-
ferences (vide infra) and this is not observed. Analogous results 
are observed with the uninfected and infected (Me7) detergent-
solubilized extracts of mouse brain homogenates (MBH) (Fig. 5). 
Thus, antibodies can be used to detect amino acids that are cova-
lently modified by the tMAB-NHS and Ac-NHS reagents.
This approach does not use proteinase K (PK), so a compari-
son between PK digestion and chemical modification was per-
formed. Infected (263K) and uninfected HBH samples were 
reacted with tMAB or proteinase K (PK) (50 mg/mL; 37°C; 
1 h). The samples were analyzed by western blot, probed with 
3F4 (Fig. 4F). The PrPC signal from the uninfected HBH was 
eliminated by either PK digestion or reaction with tMAB-NHS. 
The signal for PrPSc was present in samples treated with PK or 
with an antibody can be used to distinguish between these epit-
opes. Those epitopes that have reacted with the reagent will not 
be recognized by the antibody, while those that have not reacted 
will be recognized. In this way an antibody can be used in a novel 
way to determine which epitope is on the surface of PrPC or PrPSc 
and which is not. This approach relies on antibody recognition 
to identify accessible amino acids and is not dependent on mass 
spectrometry.
In order to test this approach, seven commercially available 
antibodies and two small molecule reagents were selected. The 
NHS esters of acetic acid (Ac) and 4-trimethylamoniumbutyric 
acid [(3-carboxypropyl)trimethylammonium chloride] (tMAB) 
were selected as the two small molecule reagents. The epitopes of 
these seven antibodies have been determined by other research-
ers and are shown in Figure 1.16-21 Four of these antibodies, 3F4, 
6D11, AH6 and GE8, were empirically determined to have an 
epitope that was no longer recognized by the antibody after react-
ing with either reagent. Amidation of ε-amino group of lysine is 
the most likely reason for the loss of recognition by the antibodies 
3F4, 6D11 and GE8. Esterification of the hydroxyl of serine or 
tyrosine is the reason for the loss of recognition by the antibody 
AH6. The three other antibodies, MAB5424, 7D9 and AG4, 
were selected as controls, because their epitopes were not modi-
fied by the reagents.
The reagents were prepared and reacted with detergent-
solubilized extracts of brain homogenates from 263K-infected 
hamsters, drowsy (Dy)-infected hamsters, Me7-infected mice, 
uninfected mice and uninfected hamsters and analyzed by west-
ern blotting. The results of these experiments are described.
Results
The NHS esters of acetic acid (Ac-NHS) and 4-trimentylam-
moniumbutyric acid (tMAB-NHS) were prepared by standard 
methods and reacted with recombinant Syrian hamster PrP 
(rSHaPrP). The reaction mixtures were run on SDS-PAGE and 
stained with Coomassie brilliant blue (Fig. 2). There is a distinct 
gel shift for the protein reacted with the tMAB-NHS reagent 
and not for the same reaction using the Ac-NHS reagent. Upon 
formation of a covalent bond with the protein, the tMAB-NHS 
reagent will add a positive charge to it; the Ac-NHS reagent will 
not. The extra positive charges on the protein would neutralize 
an equal number of negative charges from the SDS coating the 
protein, and result in an even larger apparent molecular weight 
when analyzed by SDS-PAGE. This is why there is a much larger 
gel shift for the protein reacted with the tMAB-NHS reagent.
The reaction of rSHaPrP with Ac-NHS was analyzed by mass 
spectrometry. This analysis showed that the reaction mixture is 
complex (Fig. 3). At least 13–20 amino acid residues reacted with 
the reagent (Fig. 3). rSHaPrP contains 12 primary amines, 11 
lysine residues and the N-terminus of the PrP molecule. Since 
NHS esters react preferentially with primary amines,10 this indi-
cates that more than just primary amines are chemically reacting 
with the NHS reagents under these conditions. Trypsin digestion 
of the Ac-NHS treated rSHaPrP yielded mostly large fragments 
due to the amidation of ε-amino group of lysine. The reaction © 2012 Landes Bioscience.
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of mouse and hamster brain extracts. Thus, the signals observed 
in the western blots are from epitopes that originated from PrPSc, 
since they did not react with the reagent.
This is further confirmed by close examination of the appar-
ent shift to higher molecular weights as a result of the reac-
tion with tMAB-NHS (Figs. 4A–C and 5A–C). The covalent 
attachment of the tMAB residue would be expected to increase 
the molecular weight of the protein and add a positive charge 
reacted with tMAB-NHS. The PK treated sample showed the 
characteristic N-terminally truncated PK-resistant core referred 
to as PrP27–30. This indicates that these reagents can be used in 
place of PK to detect the presence of prions by using a western 
blot probed with an appropriate antibody.
The detergent-solubilized extract of brain homogenates from 
the 263K-infected hamster brain or the Me7-infected mouse 
brain is not identical to that of the respective uninfected con-
trols. There may be molecules present in the infected extracts 
that are not present in the uninfected extracts. These molecules 
may prevent the reagents from completely reacting with the PrPC 
present in the sample and, thereby, generate artifactual results. 
In a separate experiment, the 263K-infected, Me7-infected and 
uninfected mouse brain extracts were spiked with rSHaPrP to 
determine if such molecules were present in the infected brain 
extracts. These results are shown in Figure 6A–C. The signal 
from the rSHaPrP is visible in the uninfected mouse brain extract, 
when probed with GE8. After reaction with either tMAB-NHS 
or Ac-NHS, the signal disappears (Fig. 6A). The signals from 
the Me7-infected brain extract are more intense than that of the 
rSHaPrP, so it is not possible to observe a decline in signal inten-
sity (Fig. 6A). When the same samples are probed with the 3F4 
antibody, there is a clear elimination of the signal from rSHaPrP 
in both the uninfected mouse brain extract and the Me7-infected 
mouse brain extract (Fig. 6B). The signal from the rSHaPrP 
spiked into the 263K-infected brain extract is eliminated when 
the extract is reacted with tMAB-NHS (Fig. 6C). This indi-
cates that although the control brain extracts and the infected 
brain extracts are not identical, they are similar enough that the 
tMAB-NHS and Ac-NHS reagents react with all of the PrPC 
present in both the uninfected control and the infected samples 
Figure 2. sDs-PAGe gel of hamster recombinant PrP (rPrP), hamster rPrP 
reacted with tMAB-Nhs (tMAB) or hamster rPrP reacted with Ac-Nhs 
(Ac). This is a black and white image of a coomassie stained sDs-PAGe 
gel.
Figure 1. cartoon of mouse and hamster PrPc. The epitopes of the antibodies 3F4 (MKhM), 6D11 (ThN QWN KPs KP), Ah6 (QVY YRP VDQ YsN QNN F) 
and Ge8 (IKQ hTV TTT) are indicated with solid lines. The epitopes of AG4 (WNT GGs RYP GQG sPG GNR YPP), 7D9 (AGA AAA GAV VGG L) and MAB5424 
(GGL G) are indicated by dashed lines. The positions of the two β-sheets (β-sheet 1 and β-sheet 2) and the three α-helicies (α-helix A, α-helix B and 
α-helix c) are indicated with dotted lines. (Adapted from Dumpitak, Prusiner).14,15© 2012 Landes Bioscience.
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could react with the tMAB-NHS reagent, so PNGase F was used 
to cleave the asparagine-linked sugar antennae,22,23 in order to 
determine if the observed gel shifts were due to covalent attach-
ment of the tMAB-NHS reagent to the protein or the sugars 
comprising the sugar antennae. A western blot of the PNGase F 
treatment of Me7-infected mouse brain extract control, reacted 
with tMAB-NHS, or reacted with Ac-NHS and uninfected 
mouse brain control is shown in Figure 6D. An analogous west-
ern blot of PNGase F treated 263K-infected hamster brain extract 
is shown in Figure 6E. PNGase F treatment removes the sugar 
antennae, but it does not alter the gel shift, which indicates that 
the gel shift is a result of the reaction with the protein and not the 
sugar residues. It is possible that the sugar components of the GPI 
anchor may react with the tMAB-NHS reagent, but since they 
contain the same sugars, this is unlikely. The observed gel shift 
from the PNGase F treated samples is similar to that observed 
when recombinant hamster PrP is reacted with the tMAB-NHS 
reagent (Fig. 2).
This approach was evaluated for its ability to distinguish 
between two strains of hamster adapted scrapie (263K and Dy). 
HBHs were prepared for both strains and each was reacted with 
either tMAB-NHS or Ac-NHS or no reagent was added. Western 
blot analysis was performed and probed with the antibodies 3F4, 
GE8, 6D11 or AG4 (Fig. 7). The intensity of the signals from both 
the Dy and the 263K strain reacted with tMAB-NHS are more 
intense than those reacted with Ac-NHS when the blots were 
probed with the mAb 6D11 or 3F4. There is a specific difference 
in signal intensity that is noticeable in the western blot probed 
with the antibody 6D11, where the signal for the diglycosylated 
band is present in the Dy sample reacted with Ac-NHS and sig-
nificantly reduced in the analogous 263K sample (Fig. 7C).
In order to verify this observation, four western blots, analo-
gous to that shown in Figure 7C were prepared and probed with 
the 6D11 antibody. The intensity of the signals was measured 
by densitometry. The ratio of the intensity of the diglycosylated 
band to that of the monoglycosylated band was determined for 
the Dy and 263K strains treated with nothing, tMAB-NHS or 
Ac-NHS. The values of this ratio for the 263K strain treated with 
nothing, tMAB-NHS or Ac-NHS were determined to be 1.3 ± 
0.1, 1.3 ± 0.1 and 0.9 ± 0.1, respectively. The analogous values 
for the Dy strain were determined to be 1.3 ± 0.1, 1.3 ± 0.1 and 
1.3 ± 0.1. A t-test confirmed that there is a statistically significant 
difference (p > 0.99) between the ratio intensity of diglycosylated 
band to that of the monoglycosylated band when Dy and 263K 
are treated with Ac-NHS. Thus, this approach can be used to 
distinguish between strains without the use of PK.
The intensities of the western blot signals are reduced after 
the reaction with tMAB-NHS or the Ac-NHS as show in 
Figures 4A–C and 5A–C. The intensity of the western blot signal 
remains fairly constant when hamster samples are probed with 
the antibodies AG4 or 7D9. A similar result is observed when the 
mouse samples are probed with the antibodies MAB5424, AG4 
or 7D9. Since these three antibodies bind to epitopes that are 
unaffected by tMAB-NHS or the Ac-NHS reagents, the loss of 
signal is not an artifact of the chemical reaction (Figs. 4D and E 
and 5D–F). Since PrPC is present in infected brain extracts, part 
to the protein. This combination of addition of mass and posi-
tive charge (cancelling out the negative charges of the some of 
the SDS molecules) results in this observed gel shift (Fig. 2). A 
comparison of the same material reacted with an equal amount 
of Ac-NHS shows no such shift for mouse and hamster samples 
(Figs. 4A–C and 5A–C). The mouse samples probed with anti-
bodies, MAB5424, AG4 and 7D9, whose epitopes are unaffected 
by reaction with tMAB-NHS, show this shift in both uninfected 
and Me7-infected mouse brain extracts (Fig. 5D–F). The ham-
ster samples probed with the antibodies AG4 and 7D9 show 
analogous shifts (Fig. 4D and E).
These results indicate that the reagents Ac-NHS and tMAB-
NHS have different reactivity toward PrPSc. The intensity of the 
western blot signals is dependent upon the reagent and the loca-
tion of the epitope. When 263K-infected hamster brain extract 
is reacted with tMAB-NHS the signal is more intense for the 
same extract reacted with the Ac-NHS when the blot is probed 
with 3F4 or 6D11 (Fig. 4A and C). When the same material 
is probed with the antibody GE8, the signal intensity is simi-
lar for 263K-infected extracts reacted with either tMAB-NHS 
or Ac-NHS (Fig. 4B). When the same material is probed with 
antibodies that do not recognize an epitope that is modified by 
tMAB-NHS or Ac-NHS (AG4 and 7D9), the signal intensities 
are comparable (Fig. 4C and D). Analogous results are observed 
in Me7-infected mouse brain extracts (Fig. 5A–F). This suggests 
that structural information may be obtained by the use of reagents 
with different chemical structures and chemical reactivity.
The signals from the western blot indicate that prions have 
a number of surface exposed functionalities that react with the 
reagent, which account for the observed gel shifts when the 
tMAB-NHS reagent is used. Both PrPC and the PrPSc contain a 
GPI anchor and asparagine-linked sugar antennae.2 In principle 
the sugar residues in both the sugar antennae and GPI anchor 
Figure 3. Mass distribution of recombinant hamster PrP before and 
after reaction with the Ac-Nhs reagent. Distributions are normalized 
and offset for clarity. Unreacted hamster recombinant PrP (b). hamster 
recombinant PrP reacted with Ac-Nhs reagent (20 mM concentration) 
(a). Ac is the mass difference corresponding to the addition of acetate 
(42 Da). [O] is the mass difference corresponding to the addition of 
oxygen (16 Da) to methionine.© 2012 Landes Bioscience.
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monoclonal antibodies. This differentiation is accomplished 
without the use of PK (Figs. 4 and 5). When rSHaPrP was spiked 
into infected mouse (Me7) and hamster (263K) samples and the 
samples were reacted with tMAB-NHS or Ac-NHS, the signal 
from rSHaPrP was no longer observed (Fig. 6A–C), indicating 
that the infected homogenates do not possess molecules that 
would prevent their complete reaction with the PrPC present in 
those samples. Furthermore, this approach can be used to dis-
tinguish two strains of hamster-adapted scrapie, 263K and Dy, 
without the use of PK (Fig. 7). Based on the observed gel shifts, 
a number of additional amino acid residues in both the PrPC and 
the PrPSc isoforms react with these reagents (Fig. 6D and E), 
which suggests that if this set of antibodies was enlarged more 
information on the structural differences between the isoforms 
could be obtained. This approach can be used to distinguish 
of this reduction in signal intensity is from the loss of the signal 
from the PrPC. Another possible contribution to this loss of signal 
intensity may be due to the reaction of smaller PrPSc multimers, 
the so-called proteinase K sensitive portion of the mixture.24,25 
The differences in signal intensity for those samples reacted with 
tMAB-NHS or Ac-NHS are due to the structural differences of 
the reagents’ non-reactive side chains (methyl vs. propyltrimeth-
ylammonium), since both possess identical activated NHS ester 
groups.
Discussion
The results of this small study indicate that PrPC and PrPSc are 
covalently modified by tMAB-NHS and Ac-NHS reagents 
to different extents. These modifications can be employed to 
distinguish PrPSc from PrPC using western blots probed with 
Figure 4. Western blots of infected (263K) or uninfected hamster brain extracts (hBh). samples consist of brain extracts reacted with Ac-Nhs, tMAB-
Nhs, proteinase K (PK) or brain extract controls with no added reagents. Identical amounts of the same reaction mixtures ±tMAB-Nhs, ±Ac-Nhs or 
PK with either uninfected hBh or 263K-infected hBh (263K) were probed with either the 3F4 (A), Ge8 (B), 6D11 (c), AG4 (D) or 7D9 (e) antibodies. A 
comparison of samples of brain extract controls with no added reagents or samples treated with tMAB or PK (50 mg/mL; 37°c; 1 h) is also shown (F).© 2012 Landes Bioscience.
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of the hamster PrP (3F4 epitope) and the tyrosine and/or serine 
between β-sheet 2 and α-helix B of mouse PrP (AH6 epitope) are 
not surface exposed in the respective PrPSc isoforms, but are in 
the respective PrPC isoforms.
The epitopes for the GE8 (IKQ HTV TTT) and 6D11 (THN 
QWN KPS KP) are common to both mouse and hamster PrP.16,18 
The covalent modification of the lysine by these reagents is the 
most likely cause of the signal loss observed in the western blots 
probed with GE8 (Figs. 4B and 5B), although covalent modifica-
tion of one or more of the threonines cannot be ruled out. Again, 
the covalent modification of one or both of the lysines present is 
the most likely cause of the signal loss observed in the western 
blots probed with 6D11 (Figs. 5C and 6C), although covalent 
modification of the serine or threonine is possible. These results 
suggest that the lysine residue near the glycosylation site present 
in α-helix B (GE8 epitope) and the lysine residues nearest the site 
of PK cleavage (6D11 epitope) are not surface exposed in the PrPSc 
between PrP isoforms, including prion strains, without the use 
of PK.
In addition to distinguishing between isoforms this approach 
can be used to identify the specific amino acid residues that 
react in a conformation-dependent manner with these reagents 
(Fig. 1). The epitope for the 3F4 antibody is found in hamster but 
not mouse PrP.26-28 The lysine present in this epitope (MKHM) 
is the only amino acid that forms a stable covalent bond with 
these reagents and its covalent modification would account for 
the observed signal loss when probed with 3F4 (Fig. 4A). The 
epitope for the AH6 antibody is (QVY YRP VDQ YSN QNN 
F) is found in mouse, but not hamster PrP.16,20 The sole differ-
ence between the two regions is the replacement of the serine (S) 
with an asparagine (N) in hamster. This suggests that either the 
serine, the adjacent tyrosine or both is/are covalently modified by 
the reagents, resulting in the loss of signal apparent in the west-
ern blot analysis (Fig. 5A). The lysine in the unstructured region 
Figure 5. Western blots of infected (Me7) or uninfected mouse brain extracts (MBh). samples consist of brain extracts reacted with Ac-Nhs, tMAB-Nhs 
or brain extract controls with no added reagents. Identical amounts of the same reaction mixtures ± tMAB-Nhs or ± Ac-Nhs with either uninfected 
MBh or Me7-infected MBh (Me7) were probed with either the Ah6 (A) Ge8 (B), 6D11 (c), MAB5424 (D), AG4 (e) or 7D9 (F) antibodies.© 2012 Landes Bioscience.
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This approach of combining chemical modification with anti-
body-based detection is a convenient means of analyzing PrPSc. It 
can be used to identify accessible amino acids, based on antibody 
recognition. The approach is much simpler than a mass spec-
trometry-based approach and has been successfully employed to 
identify a chemical modification that would have been very dif-
ficult to detect using mass spectrometry.32 This indicated that 
this approach is not limited to the NHS activated ester chemistry. 
It can be used to detect PrPSc in the presence of PrPC without 
the need to use PK. This approach can be used to distinguish 
among strains. It provides an additional use for the large number 
of available anti-PrP antibodies.
isoform, but are in the PrPC isoform in both mouse and hamster 
PrP. This suggests common structural elements in the mouse-
adapted (Me7) and hamster-adapted (263K) forms of scrapie.
The epitopes for the AG4, 7D9 and MAB5424 antibodies have 
been characterized (Fig. 1).18,19 Although none was empirically 
determined to have an epitope that reacted with either reagents, 
they proved to be useful controls (Figs. 4D and E and 5D–F). 
These results indicate that the effect of the reagents is a specific 
chemical modification and not a non-specific destruction of the 
mouse or hamster PrP.
The intensity of the signals from the western blots is depen-
dent upon the structure of the reagent. tMAB-NHS and Ac-NHS 
both possess the same activated ester functionality; they differ in 
terms of charge and steric bulk. Both Me7-infected mouse brain 
extracts and 263K-infected hamster brain extracts react equiva-
lently with the epitope recognized by the GE8 antibody (Figs. 4B 
and 5B). In 263K-infected hamster brain extract, the epitope rec-
ognized by the antibodies 3F4 and 6D11 is much more reactive 
to Ac-NHS than to tMAB-NHS. A similar situation is observed 
in Me7-infected mouse brain extracts when the western blots are 
probed with the antibodies AH6 and 6D11. This indicates that in 
the PrPSc conformation, the GE8 epitope has limited availability 
to either reagent. In contrast, the 3F4, AH6 and 6D11 epitopes 
are more susceptible to reaction with the Ac-NHS than tMAB-
NHS. It is not clear if this is due to the steric bulk or charge dif-
ferences between these molecules. It does indicate that exploiting 
steric bulk and charge may provide additional structural infor-
mation about PrPSc.
The difference in the reduction of the WB signal for the 
Ac-NHS as opposed to that of tMAB-NHS may be due to 
changes in the secondary structure of the protein as a result of 
covalent modification. Reaction with Ac-NHS would covalently 
convert a polar group (amine or hydroxyl) into a non-polar spe-
cies. The tMAB-NHS reagent would convert those polar groups 
to a positively charged species, although the charge would be a 
further five carbons distant. Such changes could disrupt the sec-
ondary structure of PrPSc and, thereby, expose formerly buried 
amino acid side chains.
The Dy and 263K strains differ in their susceptibility to PK 
and denaturation by guanidine hydrochloride solutions.3,29-31 PK 
digestion of Dy yields a PrP 27–30 that has at least 10 fewer 
N-terminal amino acids than does the PrP 27–30 from the 
263K strain.30 Dy is much more readily disaggregated by gua-
nidine hydrochloride, than is the 263K strain.3,31 This suggests 
that of the two strains, the Dy strain should be more susceptible 
to changes in the secondary structure induced by the covalent 
modification of amino acid side chains. When these strains are 
reacted with Ac-NHS and tMAB-NHS, it is the Dy strain that 
reacts less with these reagents than does the 263K strain (Fig. 7). 
This is especially apparent when the reaction mixture is probed 
with the mAb 6D11 (Fig. 7C), whose epitope is nearest the 
N-terminus of PrP 27–30 (Fig. 1). In contrast, the signal intensi-
ties are comparable when the reaction mixtures are probed with 
the GE8 antibody, whose epitope is contained in α-helix B and 
far from the N-terminus (Fig. 7B). These results suggest that the 
changes in secondary structure are minimal.
Figure 6. Western blots of infected (Me7 or 263K) or uninfected mouse 
brain extracts (MBh). samples consist of brain extracts reacted with Ac-
Nhs, tMAB-Nhs or brain extract controls with no added reagents. MBh 
and Me7 spiked with hamster rPrP and then reacted with tMAB-Nhs or 
Ac-Nhs or control (no added reagent) and then probed with Ge8 (A) or 
3F4 (B). 263K-infected hamster brain extract (spiked with hamster rPrP) 
± tMAB-Nhs (c). Me7-infected mouse brain extract control or Me7-
infected mouse brain extract reacted with tMAB-Nhs or Ac-Nhs and 
deglycosylated with PNGaseF or PNGaseF deglycosylated uninfected 
mouse brain extract (probed with Ge8) (D). 263K-infected hamster brain 
extract control or 263K-infected hamster brain extract reacted with 
tMAB-Nhs or Ac-Nhs and deglycosylated with PNGaseF (probed with 
3F4) (e).© 2012 Landes Bioscience.
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The synthesis of the N-hydroxysuccinimide ester of 4-trimeth-
ylamoniumbutyric acid [(3-carboxypropyl)trimethylammonium 
chloride] (tMAB) has been described previously in reference 34. 
The structures of these synthetic compounds were verified by 
NMR. Each reagent was dissolved in DMSO to make a 200 mM 
stock solution.
Production of recombinant PrP. Recombinant PrP was 
obtained from plasmids expressing the protein sequence. The 
plasmids (pET-11a; Merck KGaA) expressing the hamster and 
mouse sequences were a gift from Prof Dr Carsten Korth. The 
plasmids were cloned into BL21 cells (EMD Chemicals, Inc.). 
The molecular weight of each protein was verified by mass 
spectrometry. All of the  recombinant proteins contained an 
N-terminal methionine.35 The recombinant proteins were puri-
fied by standard procedures.
Isolation and purification of recombinant PrP.36  Washed 
inclusion bodies were isolated according to established proce-
dures.37 The inclusion body pellet was suspended in 1 mL of dena-
turing buffer (6 M guanidine hydrochloride, 100 mM sodium 
phosphate, 10 mM Tris, pH 8.0) and sonicated for 3 min. After 
sonication the suspension was centrifuged at 20,000x g for 5 min 
to remove any insoluble material. The supernatant was applied 
to a 1 mL HIS-Select cartridge (Sigma Corporation) that had 
previously been stripped and recharged with copper according 
to the manufacturer’s instructions. The denatured recombinant 
protein bound to the cartridge was renatured by the application 
of a 5 h linear gradient (0.04 mL/min) starting with 100% dena-
turing buffer and ending with 100% refolding buffer (100 mM 
sodium phosphate, 10 mM Tris, pH 8.0). After the gradient 
was completed the cartridge was washed for a further hour with 
refolding buffer at a flow rate of 0.05 mL/min. The refolded 
protein was eluted with 5 mL of 0.1 M EDTA and immediately 
dialyzed against 1 L of 100 mM ammonium acetate pH 4.5 
overnight at room temperature, using a dialysis cassette (7000 
MWCO; Thermo Scientific). The next day the dialysis buffer 
Materials and Methods
Chemicals. The 3F4 antibody was obtained from Covance. The 
MAB5424 antibody was obtained from Millipore Corporation. 
The antibodies AG4, AH6 and GE8 were obtained from the TSE 
Resource Center (now in the Roslin Institute, Scotland, UK). 
The antibodies 6D11 and 7D9 were purchased from Santa Cruz 
Biotechnology. A secondary antibody, AP-Goat Anti-Mouse IgG 
(H + L), was obtained from Invitrogen. The other two secondary 
antibodies, Anti-Mouse IgG (Fab specific)-AP and Anti-Mouse 
IgG (Fc specific)-AP (both antibodies produced in goat), were 
purchased from Sigma-Aldrich. PNGaseF was obtained from 
New England Biolabs. Proteinase K was acquired from Invitrogen. 
The MOPS and MES running buffers and LDS loading buffers 
were obtained from Invitrogen. PVDF Membranes (0.2 mm pore 
size) were obtained from Invitrogen. Novex NuPAGE 4–12% 
Bis-Tris Gels, either 1.5 mm × 15 well or 1.5 mm × 10 well were 
obtained from Invitrogen. Precise 8–16% protein gels 1 mm × 10 
wells were obtained from Thermo Scientific. StartingBlock T20 
(PBS) blocking buffer was obtained from Thermo Scientific. 
HPLC grade water was purchased from Burdick and Jackson. 
Acetonitrile, HPLC grade, was from Fisher Scientific. Trypsin 
(porcine, sequencing grade, modified) was purchased from 
Promega. All other reagents were from Sigma-Aldrich.
Synthesis of the Ac-NHS and tMAB-NHS reagents.33 One 
gram of dicyclohexylcarbodiimide (4.8 mM) was dissolved in 
20 mL of ethyl acetate and allowed to stir at room temperature. 
250 mL of acetic acid (4.3 mM) and 0.5 g of N-hydroxysuccinimide 
(4.3 mM) were added to the stirred solution. The resulting solu-
tion was allowed to stir overnight. The white precipitate from 
the reaction mixture was removed by filtration. The ethyl acetate 
was removed in vacuo to yield a yellow oil. The oil was dissolved 
in a small volume of 10% ethyl acetate in hexanes and chroma-
tographed on silica gel to yield a fraction containing the desired 
product. The solvent was removed in vacuo to yield a white solid. 
Figure 7. Western blots of 263K or drowsy (Dy) strain of hamster-adapted scrapie infected hamster brain extracts (hBh). samples consist of brain 
extracts reacted with Ac-Nhs, tMAB-Nhs or brain extract controls with no added reagents. Identical amounts of the same reaction mixtures ± tMAB-
Nhs, ±Ac-Nhs with either 263K or Dy-infected hBh were probed with either the 3F4 (A), Ge8 (B), 6D11 (c) or AG4 (D) antibodies.© 2012 Landes Bioscience.
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Me7-infected mouse and 263K-infected hamster clarified brain 
extracts. The reaction was allowed to proceed for 15 min at room 
temperature. After 15 min, 30 μL of 1 M Tris was added and 
allowed to react for 15 min.
The solutions derived from the 263K-infected and Dy-infected 
clarified hamster brain extracts and Me7-infected clarified mouse 
brain extracts (spiked and unspiked) were denatured by addition 
of a sufficient amount of 8 M guanidine hydrochloride to achieve 
a final concentration of 6 M.42 The resulting solution was allowed 
to stand for 24 h at room temperature.
Protein was precipitated with ice-cold methanol (85% metha-
nol to 15% protein solution) in microcentrifuge tubes. The tubes 
were centrifuged (20,000x g for 20 min) in a chilled rotor (-9°C) 
with an Eppendorf Model 5417R centrifuge. The methanol 
supernatant was discarded and the pellet washed with methanol 
and centrifuged again under the same conditions. The methanol 
supernatant was discarded and the pellet was allowed to air dry 
for 15 min. The pellet was dissolved in 240 μL of 2x LDS buffer 
(Invitrogen) and put in boiling water for 10 min. These solutions 
in LDS were used for western blotting.
Mass spectrometry. Whole protein mass spectrometry 
(NanoLC/ESI/MS) was performed with an Applied Biosystems 
(ABI/MDS SCIEXa) model QStar Pulsar equipped with a 
Proxeon Biosystems nanoelectrospray source. The instrument 
was equipped with a NanoLC system (Dionex) that includes an 
autosampler, column switching device, loading pump and nano-
flow solvent delivery system. The signals were processed with the 
Bayesian protein reconstruct feature of the software.
Ten micrograms of recombinant Syrian hamster PrP 
(rSHaPrP) was dissolved in 90 μL of reaction buffer (2% w/v 
β-octylglucopyranoside, 20 mM sodium phosphate pH 7.2, in 
water). The solution was split into two portions; one portion was 
reacted with the Ac-NHS reagent and the other with the tMAB-
NHS reagent (vide supra). After quenching, the two samples 
were precipitated with methanol (vide supra). The sample reacted 
with the Ac-NHS reagent was analyzed by mass spectrometry. 
The sample reacted with tMAB-NHS or Ac-NHS was analyzed 
by SDS-PAGE (Precise 8–16% protein gels 1 mm × 10 wells) and 
stained with Coomassie brilliant blue.
Densitometry. Densitometry measurements were made 
using the AlphaEaseFC version 4.0.0 software (Alpha Innotec 
Corporation) with black having a value of 255 and white having a 
value of 0. The statistical analysis was performed with Microsoft 
Excel.
Western blots. The protein gels (NuPAGE 1.5 mm thick 10- 
or 15-well) were purchased from commercial vendors and used 
according to manufacturer’s instructions. The gels, thick blot-
ting paper and PVDF membrane were soaked in transfer buffer 
(25 mM Tris, 250 mM glycine in 15% methanol) for 10 min 
prior to using the BIO-RAD Trans-Blot SD semi-dry transfer 
cell for 50 min at 100 mA. After the transfer was complete, the 
PVDF membrane was placed into a square Petri dish (10 × 10 cm) 
and gently agitated in 20 mL of wash buffer (PBS + 0.05 Tween 
20) for 5 min. After 5 min the wash buffer was discarded and 
the membrane was blocked for 15 min in 10 mL of StartingBlock 
T20 with gentle agitation. After 15 min, one microliter of the 
was discarded and replaced with 1 L of fresh buffer and allowed 
to dialyze for 2 h. Aliquots were lyophilized and quantitated by 
BCA protein assay (Thermo Scientific). The molecular weight of 
the proteins predicted by the prnp gene sequences matched that 
observed by mass spectrometric analysis.
Animal handling and obtaining infected brains. LVG Syrian 
golden hamsters and Swiss CD-1 mice were obtained from com-
mercial sources (Charles River Laboratories). Uninfected ham-
ster and mouse brains were harvested from uninfected animals 
obtained from commercial sources (Charles River Laboratories).
The 263K (=Sc237),38,39 and the drowsy (Dy),40 strains of 
hamster-adapted scrapie were obtained from InPro Biotechnology 
and passaged once through LVG Syrian golden hamsters (Charles 
River Laboratories). The Me7 strain of mouse-adapted scrapie41 
was obtained from InPro Biotechnology and passaged once 
through Swiss CD-1 mice (Charles River Laboratories).
One brain each from an uninfected hamster, a 263K-infected 
hamster, a Dy-infected hamster, an uninfected mouse and an Me7-
infected mouse was separately homogenized using an Omni GLH 
general laboratory homogenizer and disposable Omni Tip plastic 
generator probes in phosphate buffered saline (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4) to make a 10% 
brain homogenate in a 15 mL plastic tube. An aliquot of each of 
these five brain homogenates was transferred into a plastic micro-
centrifuge tube and mixed with a sufficient volume of a 10% (w/v) 
solution of the detergent β-octylglucopyransoide (BOG) and a 
sufficient volume of 500 mM sodium phosphate solution (pH 7.2) 
to make a detergent-solubilized brain extract in 2% (w/v) BOG 
and 20 mM phosphate pH 7.2. Each of the five resulting detergent 
solutions was centrifuged (20,000x g, 15 min) at room tempera-
ture to clarify the solutions and yield the respective detergent-sol-
ubilized brain extracts. These five clarified detergent-solubilized 
brain extracts were used for the described reactions.
Reaction of the brain extracts with Ac-HNS or tMAB-NHS 
reagents. The five clarified brain extracts were used in the reac-
tions described below. Three 270 μL aliquots of each of the brain 
extracts were placed in 15 separate microcentrifuge tubes. Thirty 
microliters of the tMAB-NHS reagent stock was added to one 
tube from each of the five clarified extracts and mixed. The same 
amount of the Ac-NHS stock solution was added to another tube 
from each of the five clarified extracts and mixed. The last of the 
three aliquots was left as a control. The reaction was allowed to 
proceed for 15 min at room temperature. After 15 min, 30 μL 
of a 1 M Tris solution (5 equivalents) was added to each of the 
15 tubes and mixed. These solutions were allowed to stand for 
15 min at room temperature.
In addition to the previously described reactions, separate 
samples of the Me7-infected or 263K-infected clarified brain 
extracts were spiked with mouse or hamster recombinant PrP, 
respectively. Two aliquots of 270 μL of the Me7-infected mouse 
or 263K-infected clarified brain extracts were transferred to four 
microcentrifuge tubes. One microliter of a solution containing 
either mouse or hamster recombinant PrP (~600 ng) was added 
to the two Me7-infected mouse or two 263K-infected hamster 
samples, respectively. Thirty microliters of the tMAB-NHS 
reagent was added to one of the recombinant spiked samples of © 2012 Landes Bioscience.
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primary antibody (3F4, AH6, GE8 or MAB5424; concentra-
tion 1–2 mg/mL) was added to 10 mL of blocking buffer and 
incubated with the membrane for 1 h at room temperature. 
After 1 h the blocking buffer containing the primary antibody 
was discarded and 20 mL of wash buffer was added and gently 
agitated for 5 min. The washing buffer was discarded and three 
additional wash steps were performed. After the four wash steps 
were completed, 10 mL of blocking buffer containing 10 μL of 
the secondary antibody, AP-Goat Anti-Mouse IgG (H + L), was 
added. The membrane was incubated at room temperature for 
45 min. After 45 min the membrane was washed four times at 
five-minute intervals.
After the washing was complete the blot was placed in 10 mL 
of a Sigma/FAST BCIP/NBT solution (1 tablet per 10 mL per 
manufacturer’s instructions) and incubated at 37°C. After devel-
opment, the blots were dried and scanned.
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